Published in final edited form as:

Thorax. 2019 November ; 74(11): 1099–1101. doi:10.1136/thoraxjnl-2019-213621.

Growth differentiation factor-15 as a biomarker of strength and recovery in survivors of acute respiratory failure

Brian Rosenberg, MD, PhD¹, Michio Hirano, MD², Catarina Quinzii, MD², Elizabeth Colantuoni, PhD³, Dale M. Needham, MD, PhD^{4,5}, David J. Lederer, MD, MS^{1,6}, Matthew R. Baldwin, MD, MS¹

¹Division of Pulmonary, Allergy, and Critical Care, Columbia University Vagelos College of Physicians and Surgeons, New York, NY;

²Division of Neuromuscular Disorders, Columbia University Vagelos College of Physicians and Surgeons, New York, NY;

³Department of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD;

⁴Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD;

⁵Department of Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, MD;

⁶Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY.

Abstract

Muscle mitochondrial dysfunction is implicated in ICU-acquired weakness, but there is no serum biomarker of muscle mitochondrial function. Higher serum growth differentiation factor-15 (GDF-15) is a biomarker of inherited mitochondrial myopathy disease, and is associated with mortality in several age-related diseases. Among 142 older (age ≥ 65) survivors of acute respiratory failure, we found that higher serum GDF-15 measured during the week prior to hospital discharge was cross-sectionally associated with weaker diaphragm, limb, and hand-grip strength, and longitudinally associated with lower rates of functional recovery over 6 months, independent of age, sex, pre-existing disability, comorbidity, frailty, APACHE-II scores, and concurrent interleukin-6 levels.

Survivors of acute respiratory failure often develop skeletal muscle weakness that results in disability.¹ Patients with ICU-acquired weakness (ICUAW), defined as a Medical Research Council (MRC) sumscore <48,² have decreased skeletal muscle mitochondrial content and

Corresponding Author: Matthew R. Baldwin, MD, MS, 622 West 168th Street, PH-8E, Room 101, New York, NY 10032.

Contributorship Statement: Study Design and concept: MRB, MH; Acquisition, analysis, or interpretation of data: BR, DJL, MRB, EC, DMN; Drafting of the manuscript: BR, MRB; Critical revision of the manuscript: MRB, MH, CQ, DMN, DJL, EC, MRB. Statistical Analysis: BR, MRB EC, DJL. Study Supervision: MRB. Drs. Rosenberg and Baldwin had full access to all of the data in the study and take responsibility of the integrity of the data and accuracy of the data analysis.

Competing Interests: The authors report no competing interests.

impaired oxidative phosphorylation,³⁴ but whether skeletal muscle mitochondrial dysfunction affects strength and disability in the larger population of ICU survivors with weakness less severe than ICUAW is unknown. Clinical studies of mitochondrial function in critical illness are often limited to case-control studies with small sample sizes because the measurement of tissue mitochondrial function requires biopsy and time-intensive and costly laboratory assessments.^{3–5}

Serum growth differentiation factor-15 (GDF-15) has been identified as a sensitive biomarker of inherited mitochondrial diseases.⁶ GDF-15 is a member of the transforming growth factor- β cytokine family, and identifying its receptors and downstream effects is an area of active investigation. While it is released from many tissues in response to cellular stress or injury, its expression is markedly upregulated in skeletal myocytes of patients with mitochondrial myopathy diseases. Higher serum GDF-15 levels have been associated with older age, higher body mass index (BMI), diabetes, cardiovascular, renal, liver, and chronic obstructive pulmonary disease, and some cancers. Independent of these conditions, serum GDF-15 is emerging as a potential marker of skeletal muscle mitochondrial dysfunction in aging and age-related disorders.^{6–8} We hypothesized that higher levels of GDF-15 would be independently associated with worse muscle strength and functional recovery in older survivors of acute respiratory failure.

We examined 142 acute respiratory failure survivors in the Frailty and Outcomes in Critical Illness Survivors (FOCIS) study. Details of the cohort have been published previously.⁹ Participants were 65 years old, received >24 hours of non-invasive or invasive mechanical ventilation, and underwent assessment of the basic Activities of Daily Living (ADLs) at hospital discharge and 1, 3, and 6 months later. We also asked participants or their surrogate about ADL disability and frailty (via the Clinical Frailty Scale¹⁰) in the month prior to hospitalization. During the week prior to hospital discharge, while on the general ward, we measured BMI, diaphragmatic strength (via sniff nasal inspiratory pressure according to American Thoracic Society recommendations¹¹), limb strength (via manual muscle testing (MRC sumscore)¹²), dominant-hand grip strength (highest of three measurements with the Jamar Plus+ dynamometer (Patterson Medical, IL)), and serum GDF-15 and interleukin-6 (IL-6) concentrations (Quantikine ELISA, R&D Biosystems, Minneapolis, MN). We examined cross-sectional associations between natural log-transformed GDF-15 and the muscle strength measurements using generalized additive linear models with LOESS smoothers, and since there was no evidence for nonlinearity, we derived effect estimates from linear models. We examined longitudinal associations between log-transformed GDF-15 and functional recovery using additive Cox models with penalized splines, and since there was no evidence for nonlinearity, we estimated recovery rate ratios using competing risk survival regression (*stcrreg* command, Stata 15.1). We defined recovery as returning to an ADL disability count less than or equal to the pre-hospitalization count within 6-month follow-up. We measured time to recovery as the number of days from ICU discharge until the date of the follow-up assessment at which recovery was first achieved (i.e., hospital discharge, 1-, 3-, or 6-month follow-up). Decedents were censored at the time of death if they had not already recovered. We excluded ten FOCIS pilot cohort participants (7%) who never had disability follow-up, and 4 FOCIS main cohort participants (3%) who were lost to follow-up. We adjusted for age, sex, BMI, pre-hospitalization ADL disability

count and frailty, Acute Physiology and Chronic Health Evaluation (APACHE)-II score, IL-6, and the presence of any diabetes, renal disease, liver disease, prior myocardial infarction, congestive heart failure, chronic pulmonary disease, or any cancer, based on Charlson comorbidity index criteria.⁷¹³ We confirmed the proportional hazards assumption of the Cox models using the Schoenfeld residuals test.

The mean (SD) age of participants was 74 (8) years, median (IQR) pre-hospitalization ADL disability count was 0 (0–1), mean (SD) APACHE II score was 29 (8), median (IQR) hospital discharge ADL disability count was 4 (1–5), with 21 (15%) dying and 91 (64%) recovering in a median (IQR) 45 (7–113) days. The median (IQR) GDF-15 level was 3,216 (2,060–4,771) pg/ml. Those in higher GDF-15 quartiles tended to have more comorbidities, higher APACHE II scores, invasive mechanical ventilation, longer ICU length of stay, discharge to a skilled-care facility, and death within six months (Table). GDF-15 had statistically significant and linear inverse cross-sectional associations with measures of muscle strength (Figure panels A–C). For 1 SD decrease in sniff force (20 cmH₂O), GDF-15 increased 17% (95%-CI: 5.1–27%); for 1 SD decrease in MRC score (5.7), GDF-15 increased 14% (95%-CI: 3.4–23%); and, for 1 SD decrease in hand-grip strength (8.7 kg), GDF-15 increased 13% (95%-CI: 1.9–23%). GDF-15 had a statistically significant and linear association with the ADL recovery rate (Figure panel D). For every 1 natural log increase in GDF-15, the rate of ADL recovery decreased 57% (95%-CI: 31–74%).

In older acute respiratory failure survivors, we demonstrated that higher serum GDF-15 levels were independently associated with weaker diaphragm, limb, and hand grip strength during the week prior to hospital discharge, and lower rates of ADL recovery over 6-month follow-up. Prior studies have reported that GDF-15 improves in-hospital mortality prediction when added to the APACHE-III for ARDS patients,¹⁴ and that serum GDF-15 and muscle GDF-15 mRNA are elevated in cardiothoracic-ICU patients with ICUAW compared to elective cardiac surgery controls.¹⁵¹⁶ Our findings suggest that GDF-15 has potential as a biomarker to risk stratify ICU survivors for functional recovery during the post-ICU period on the general ward when post-acute care is being considered.

Our work is preliminary. The observed associations are subject to unmeasured and residual confounding. Future studies in ICU survivors should correlate serum GDF-15 levels with direct measures of muscle mitochondrial function and muscle GDF-15 expression as serum GDF-15 could also be elevated due to other tissue or organ injury in ICU survivors. Our results need to be externally validated in a cohort that also includes younger adult ICU survivors. Future work should examine the predictive utility of GDF-15 from the onset of critical illness through the early post-hospitalization period. Despite these limitations, our findings support further study of GDF-15 as a potential serum biomarker of skeletal muscle mitochondrial function in ICU survivors that may be valuable as a predictive or prognostic enrichment tool in early phase trials of post-ICU rehabilitation or novel therapies aimed at improving post-ICU disability.

ACKNOWLEDGEMENTS

Funding: Dr. Baldwin is supported by NIH grant K23 AG045660, a faculty research fellowship from the Columbia University Aging Center, and the Columbia University Irving Institute (NIH grant UL1 TR001873). Drs. Quinzii

and Hirano are supported by NIH grant P01 HD080642. Dr. Hirano is also supported by NIH grant U54 NS078059. Dr. Lederer is supported by NIH grants R01 HL103676, R01 HL137234, and K24 HL131937.

REFERENCES

1. Fan E, Dowdy DW, Colantuoni E, et al. Physical complications in acute lung injury survivors: a two-year longitudinal prospective study. *Critical care medicine* 2014;42(4):849–59. doi: 10.1097/ccm.000000000000040 [published Online First: 2013/11/20] [PubMed: 24247473]
2. De Jonghe B, Sharshar T, Lefaucheur JP, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. *JAMA* 2002;288(22):2859–67. [published Online First: 2002/12/11] [PubMed: 12472328]
3. Dos Santos C, Hussain SN, Mathur S, et al. Mechanisms of Chronic Muscle Wasting and Dysfunction after an Intensive Care Unit Stay. A Pilot Study. *American journal of respiratory and critical care medicine* 2016;194(7):821–30. doi: 10.1164/rccm.201512-2344OC [published Online First: 2016/04/09] [PubMed: 27058306]
4. Jiroutkova K, Krajcova A, Ziak J, et al. Mitochondrial function in skeletal muscle of patients with protracted critical illness and ICU-acquired weakness. *Critical care (London, England)* 2015;19:448. doi: 10.1186/s13054-015-1160-x [published Online First: 2015/12/25]
5. Carre JE, Orban JC, Re L, et al. Survival in critical illness is associated with early activation of mitochondrial biogenesis. *American journal of respiratory and critical care medicine* 2010;182(6):745–51. doi: 10.1164/rccm.201003-0326OC [published Online First: 2010/06/12] [PubMed: 20538956]
6. Davis RL, Liang C, Sue CM. A comparison of current serum biomarkers as diagnostic indicators of mitochondrial diseases. *Neurology* 2016;86(21):2010–15. doi: 10.1212/WNL.0000000000002705 [PubMed: 27164684]
7. Fujita Y, Taniguchi Y, Shinkai S, et al. Secreted growth differentiation factor 15 as a potential biomarker for mitochondrial dysfunctions in aging and age-related disorders. *Geriatrics & gerontology international* 2016;16 Suppl 1:17–29. doi: 10.1111/ggi.12724 [published Online First: 2016/03/29] [PubMed: 27018280]
8. Patel MS, Lee J, Baz M, et al. Growth differentiation factor-15 is associated with muscle mass in chronic obstructive pulmonary disease and promotes muscle wasting in vivo. *J Cachexia Sarcopenia Muscle* 2016;7(4):436–48. [PubMed: 27239406]
9. Baldwin MR, Singer JP, Huang D, et al. Refining Low Physical Activity Measurement Improves Frailty Assessment in Advanced Lung Disease and Survivors of Critical Illness. *Annals of the American Thoracic Society* 2017;14(8):1270–79. doi: 10.1513/AnnalsATS.201612-1008OC [published Online First: 2017/04/12] [PubMed: 28398076]
10. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. *CMAJ* 2005;173(5):489–95. doi: 10.1503/cmaj.050051 [published Online First: 2005/09/01] [PubMed: 16129869]
11. ATS/ERS Statement on respiratory muscle testing. *American journal of respiratory and critical care medicine* 2002;166(4):518–624. doi: 10.1164/rccm.166.4.518 [published Online First: 2002/08/21] [PubMed: 12186831]
12. Kleyweg RP, van der Meche FG, Schmitz PI. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barre syndrome. *Muscle & nerve* 1991;14(11):1103–9. doi: 10.1002/mus.880141111 [published Online First: 1991/11/01] [PubMed: 1745285]
13. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40(5):373–83. [published Online First: 1987/01/01] [PubMed: 3558716]
14. Clark BJ, Bull TM, Benson AB, et al. Growth differentiation factor-15 and prognosis in acute respiratory distress syndrome: a retrospective cohort study. *Critical care (London, England)* 2013;17(3):R92. doi: 10.1186/cc12737 [published Online First: 2013/05/28]
15. Bloch SA, Lee JY, Syburra T, et al. Increased expression of GDF-15 may mediate ICU-acquired weakness by down-regulating muscle microRNAs. *Thorax* 2015;70(3):219–28. doi: 10.1136/thoraxjnl-2014-206225 [published Online First: 2014/12/18] [PubMed: 25516419]

16. Bloch SA, Lee JY, Wort SJ, et al. Sustained elevation of circulating growth and differentiation factor-15 and a dynamic imbalance in mediators of muscle homeostasis are associated with the development of acute muscle wasting following cardiac surgery. *Critical care medicine* 2013;41(4):982–9. doi: 10.1097/CCM.0b013e318274671b [published Online First: 2013/01/19] [PubMed: 23328263]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure.

Continuous associations of serum GDF-15 with (A) sniff inspiratory pressure, (B) Medical Research Council (MRC) sumscore from manual muscle testing, and (C) hand grip strength using generalized additive models with LOESS smoothers for strength measurements. (D) Continuous association of serum GDF-15 with the 6-month ADL recovery rate ratio from an additive Cox model with a penalized spline for natural log-transformed GDF-15. Dotted black lines are predicted values. Blue dashed lines are 95% confidence intervals. Hash marks along the x-axis indicate individual study participants. Since there is no evidence of nonlinearity, effect estimates are derived from linear models (A-C) and a competing risk survival regression model (D). Models were adjusted for age, sex, body mass index, pre-hospitalization basic ADL disability count and Clinical Frailty Scale score, APACHE-II scores, interleukin-6 levels, and presence of diabetes, renal, liver, cardiovascular, or chronic pulmonary disease, and cancer.

Table.

Characteristics of older survivors of acute respiratory failure by quartiles of GDF-15.

GDF15 (pg/ml), range	Quartile 1 (614–2060)	Quartile 2 (2065–3193)	Quartile 3 (3240–4771)	Quartile 4 (4821–27000)
No. of Participants	n = 36	n = 35	n = 36	n = 35
Age, mean (SD)	73 (8.0)	73 (9.5)	76 (7.5)	73 (6.8)
Male, n (%)	19 (53)	13 (37)	17 (49)	15 (42)
BMI, mean (SD)	27 (7.7)	30 (8.5)	27 (6.4)	27 (5.9)
Pre-Hospitalization ADL Disability Count, ^a median (IQR)	0 (0–0)	1 (0–4.5)	0 (0–1)	0 (0–1)
Comorbidities ^b				
Diabetes, n (%)	7 (19)	13 (37)	16 (44)	15 (43)
Renal Disease, n (%)	0 (0)	1 (2.9)	8 (22)	13 (37)
Liver Disease, n (%)	2 (5.6)	0 (0)	2 (5.6)	5 (14)
Prior Myocardial Infarction, n (%)	4 (11)	6 (17)	5 (14)	8 (23)
Congestive Heart Failure, n (%)	10 (28)	16 (46)	13 (36)	12 (34)
Chronic Pulmonary Disease, n (%)	18 (50)	15 (43)	7 (20)	7 (20)
Any Cancer, n (%)	2 (5.6)	5 (14)	9 (25)	8 (23)
APACHE II score, mean (SD)	28 (8.2)	28 (6.5)	32 (8.3)	31 (7.5)
Type of Respiratory Support, n (%)				
Non-Invasive Positive Pressure				
Ventilation or High Flow Nasal Cannula only	7 (20)	10 (29)	5 (14)	4 (11)
Mechanical Ventilation	29 (80)	25 (71)	30 (86)	32 (89)
ICU Length of Stay, median (IQR)	4 (2–6)	4 (3–7)	6 (3–14)	8 (5–11)
Sniff Nasal Inspiratory Pressure (cm H ₂ O), median (IQR)	52 (35–69)	34 (28–45)	21 (18–32)	36 (28–43)
MRC Sumscore, median (IQR)	60 (59–60)	58 (56–60)	58 (54–59)	58 (53–60)
Grip Strength, Women (kg), mean (SD)	17 (4.6)	13 (6.4)	11 (6.4)	12 (6.6)
Grip Strength, Men (kg), mean (SD)	28 (9.3)	22 (8.8)	19 (5.3)	20 (7.9)
ADL Disability Count at Hospital Discharge, ^a median (IQR)	1 (0–2)	5 (2–6)	5 (3–5)	5 (2–6)
Discharge Location, n (%)				
Home	27 (75)	21 (60)	11 (31)	17 (47)
Skilled Care Facility	9 (25)	14 (40)	24 (69)	19 (53)
Mortality, n (%)	2 (5.6)	3 (8.6)	7 (20)	9 (25)

^a ADL: Activities of Daily Living (eating, toileting, bathing, dressing, walking, transferring).^b Presence of comorbidities are based on Charlson comorbidity criteria.¹³